OMG and amyotrophic lateral sclerosis: As expected, PBMCs from ALS patients and healthy controls responded weakly to peptides from the autoantigens actin or myelin oligodendrocyte glycoprotein (MOG, data available in 24/27 cases), with no significant difference between healthy controls and ALS patients.